白细胞介素6对帕金森病和血管源性帕金森综合征的临床诊断意义

The application of interleukin-6 in clinical diagnosis of Parkinson disease

目的检测帕金森病(Parkinson disease,PD)和血管源性帕金森综合征(VP)患者血浆白细胞介素6(interleukin-6,IL-6)水平的变化,并探讨其对PD和VP的临床诊断意义。方法选择16例原发性PD、18例VP患者和15名健康对照,应用固相酶联免疫法检测其血浆IL-6水平变化,并分析其与患者Webster评分的相关性。结果原发性PD患者和VP患者血浆IL-6水平〔分别为(3.6±1.9)、(6.1±2.6)pg/mL〕均高于健康对照组〔(2.5±1.8)pg/mL,P<0.01〕,且VP患者高于原发性PD患者(P<0.01)。原发性PD患者血浆IL-6水平与Webster评分无相关性,与多巴制剂的使用亦无相关性。结论 IL-6可能作为鉴别PD和VP的血浆标志物,但对病情的评估无临床意义。

Objective To detect the interleukin-6 （IL-6） concentration in the plasma of idiopathic Parkinson disease （IPD） and vascular parkinsonism （VP） patients, and to discuss its clinical application in the diagnosis of IPD and VP. Methods 16 IPD patients, 18 VP patients and 15 health controls were included, their plasma IL-6 levels were measured by solid ELISA method. Results The IL-6 level was higher in IPD group in comparison with healthy control group, and was remarkably higher in VP group in comparison with both the other two groups. The plasma IL-6 level was not correlated with Webster scale and the use of L-dopa. Conclusions The analysis of IL-6 could be used as a plasma biomarker to distinguish IPD and VP, but not useful for evaluating the state of illness.